Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
AstraZeneca
Cantor Fitzgerald
McKesson
Novartis
Teva
Johnson and Johnson
Accenture
Cerilliant
Chubb

Generated: October 23, 2017

DrugPatentWatch Database Preview

SENSIPAR Drug Profile

« Back to Dashboard

Which patents cover Sensipar, and when can generic versions of Sensipar launch?

Sensipar is a drug marketed by Amgen and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-one patent family members in thirty-four countries and seven supplementary protection certificates in seven countries.

The generic ingredient in SENSIPAR is cinacalcet hydrochloride. There are twenty-four drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cinacalcet hydrochloride profile page.

Summary for Tradename: SENSIPAR

US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list6
Bulk Api Vendors: see list91
Clinical Trials: see list16
Patent Applications: see list22
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:SENSIPAR at DailyMed

Pharmacology for Tradename: SENSIPAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004RXYesNo► Subscribe► Subscribe ► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-003Mar 8, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-003Mar 8, 2004RXYesYes► Subscribe► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004RXYesNo► Subscribe► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004RXYesNo► Subscribe► SubscribeYY ► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-002Mar 8, 2004RXYesNo► Subscribe► Subscribe ► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-003Mar 8, 2004RXYesYes► Subscribe► SubscribeYY ► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004RXYesNo► Subscribe► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-003Mar 8, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-002Mar 8, 2004RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: SENSIPAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-003Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-002Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-003Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-002Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-003Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-001Mar 8, 2004► Subscribe► Subscribe
Amgen
SENSIPAR
cinacalcet hydrochloride
TABLET;ORAL021688-002Mar 8, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for SENSIPAR

Drugname Dosage Strength RLD Submissiondate
cinacalcet hydrochlorideTablets30 mg, 60 mg and 90mgSensipar3/10/2008

Non-Orange Book Patents for Tradename: SENSIPAR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,391,210 Abrasive article► Subscribe
6,211,244 Calcium receptor-active compounds► Subscribe
5,962,314 Calcium receptor-active molecules► Subscribe
5,763,569 Calcium receptor-active molecules► Subscribe
6,001,884 Calcium receptor-active molecules► Subscribe
5,688,938 Calcium receptor-active molecules► Subscribe
5,858,684 Method of screening calcium receptor-active molecules► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SENSIPAR

Country Document Number Estimated Expiration
China1534016► Subscribe
World Intellectual Property Organization (WIPO)9511221► Subscribe
Japan5849015► Subscribe
Cyprus1113703► Subscribe
Hong Kong1053303► Subscribe
Canada2178743► Subscribe
Australia2588992► Subscribe
South Korea100251995► Subscribe
Spain2218531► Subscribe
Austria312347► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SENSIPAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1203761/01Switzerland► SubscribePRODUCT NAME: CINACALCETUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56965 27.10.2004
C/GB05/031United Kingdom► SubscribePRODUCT NAME: CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT OR COMPLEX THEREOF; REGISTERED: UK EU/1/04/292/001 20041022; UK EU/1/04/292/002 20041022; UK EU/1/04/292/003 20041022; UK EU/1/04/292/004 20041022; UK EU/1/04/292/005 20041022; UK EU/1/04/292/006 20041022; UK EU/1/04/292/007 20041022; UK EU/1/04/292/008 20041022; UK EU/1/04/292/009 20041022; UK EU/1/04/292/010 20041022; UK EU/1/04/292/011 20041022; UK EU/1/04/292/012 20041022; UK EU/1/04/293/001 20041022; UK EU/1/04/293/002 20041022; UK EU/1/04/293/003 20041022; UK EU/1/04/293/004 20041022; UK EU/1/04/293/005 20041022; UK EU/1/04/293/006 20041022; UK EU/1/04/293/007 20041022; UK EU/1/04/293/008 20041022; UK EU/1/04/293/009 200410
182Luxembourg► Subscribe91182, EXPIRES: 20191022
C020/2005Ireland► SubscribeSPC020/2005: 20060407, EXPIRES: 20191021
0199Netherlands► Subscribe
C0029France► SubscribePRODUCT NAME: CINACALCET; REGISTRATION NO/DATE: EU/01/04/292/001-012 20041022
2005 00027Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
QuintilesIMS
Harvard Business School
Moodys
US Army
Accenture
UBS
Colorcon
Baxter
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot